Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.
NCT04304508 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of antiplatelet therapy in patients following a recent non cardioembolic ischemic stroke which occurs when a blood clot that has not formed in the heart travelled to the brain. BAY 2433334, works by blocking a step of the blood clotting process in our body and thins the blood and is a so called oral FXIa inhibitor.
Conditions Studied
Interventions
- DRUG BAY2433334
- OTHER BAY2433334 matching placebo
Study Locations (20)
Victoria
- Grampians Health Ballarat — Ballarat
- Eastern Clinical Research Unit - Box Hill — Box Hill
- Royal Melbourne Hospital — Parkville
- The Alfred Hospital — Prahran
New South Wales
- Liverpool Hospital — Liverpool
- John Hunter Hospital — New Lambton
- Royal North Shore Hospital — Sydney
Queensland
- Sunshine Coast University Hospital — Birtinya
- Gold Coast University Hospital — Southport
Florida
- Univ.of South Florida College of Medicine — Tampa
Minnesota
- Minneapolis Clinic of Neurology, Ltd. — Golden Valley
Missouri
- St. Luke's Hospital of Kansas City — Kansas City
North Carolina
- Guilford Neurologic Associates — Greensboro
Pennsylvania
- University of Pittsburgh Medical Center Hamot — Erie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,808 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2022-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04304508
The ClinicalTrials.gov registry entry for NCT04304508 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,808 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 143 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Acute Non-cardioembolic Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions — of which BAY2433334 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04304508 reports 20 study locations spanning 14 distinct geographic areas — top geographies include Victoria, New South Wales, Queensland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04304508 about?
NCT04304508 is a clinical study titled "Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.". The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of antiplatelet therapy in patients following a recent non cardioembolic ischemic stroke which occurs when a blood clot that has not formed i...
What is the current status of trial NCT04304508?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,808 participants. The study started on 2020-06-15. Estimated completion is 2022-02-18.
What conditions does trial NCT04304508 study?
This clinical trial studies the following conditions: Acute Non-cardioembolic Ischemic Stroke. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04304508?
The interventions under investigation include: BAY2433334 (DRUG), BAY2433334 matching placebo (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04304508?
This trial is sponsored by Bayer, which has 143 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04304508 being conducted?
This trial has 20 study locations across Florida, Minnesota, Missouri, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.